CRUSH Life Sciences was founded in 2018 by industry colleagues Laurie Halloran, President & CEO of Halloran Consulting Group, Doug MacDougall, Managing Partner at MacDougall Advisors, and Geoff Meyerson, CEO & Co-Founder of Locust Walk. These entrepreneurs discussed ways to bring together a community of executives for off-the-record chats to talk through successes, challenges, and […]
SFBay Spotlights
Spotlight Q&A: The Story of XiltriX
/ big4bio
Stephen Tierney is the President at XiltriX North America, and is based in San Diego, California Big4Bio: What is the story of XiltriX? Tierney: XiltriX North America was established to make science safer and more predictable through technology. Over the past 30 years, XiltriX has been developed in-house by our sister company in the Netherlands. […]
Spotlight: Event Recap from 2021 DEI Report
/ big4bio
NOTE: On December 8th, Big4Bio:Philadelphia sponsor Life Sciences Pennsylvania (LSPA) conducted a virtual leadership panel with representatives from three different industries to discuss their culture, hiring practices, and managing the changing landscape of the workforce. Part 1 of a transcript recap of this event is included in our just-published 2021 DEI Report; part 2 continues […]
Spotlight: Keeping the Life Sciences Workplace Safe
/ big4bio
The Big4Bio Podcast · Keeping the Life Sciences Workplace Safe
Spotlight: Quintara Discovery — A CRO Where No Project is Too Big or Too Small
Marie Daghlian Quintara Discovery, Inc prides itself for being a flexible partner in biotech companies’ drug discovery and development efforts. Based in the San Francisco Bay Area, it provides high-quality drug discovery services to the vibrant biotech community in the region and beyond, including in vitro ADME profiling, bioanalysis services, and dedicated assay development and […]
Spotlight: The 2021 Life Sciences Workforce Trends Report for California
/ big4bio
Big4Bio sponsors Biocom and CLS have published a joint report, “2021 Life Sciences Workforce Trends,” which includes the most pressing current and projected talent needs of California’s life sciences industry, a constantly-leading driver of employment across the state. The three foundational datasets described, include the number of job postings from January 2017 to December 2020, […]
Spotlight Q&A with Stephen Ghiglieri, Danforth Advisors
/ big4bio
Stephen Ghiglieri is a veteran corporate officer of life science companies and a newly-appointed Managing Director of the Western Region for Danforth Advisors Big4Bio: As an experienced finance and operations executive, what attracted you to the life sciences? SG: I have spent the majority of my career in life sciences, but it was a departure […]
Spotlight: Explora BioLabs
/ big4bio
Leading the Nation’s Preclinical Vivarium Market Explora BioLabs provides preclinical, AAALAC-accredited vivarium space and related services to biotech clients in development stages from early startup to maturity. With nearly 200,000 square feet of space across 18 locations in biotech-dense communities, the company prides itself on providing clients the ability to initiate preclinical in vivo programs […]
The Big4Bio Company to Watch Program
September 2021: Molecular Assemblies
September 2021: Molecular Assemblies
/ big4bio
THE COMPANY/THE MISSION Changing the Paradigm for Writing DNA Molecular Assemblies’ leaders detail how the company got started, the company’s technology for synthesizing DNA, and why that technology is better than current methods. THE TECHNOLOGY, PART 1 Moving Synthetic Biology into the 21st Century A deeper look at the company’s enzymatic DNA synthesis […]
The Big4Bio Company to Watch Program
July 2021: Meissa Vaccines
July 2021: Meissa Vaccines
/ big4bio
THE COMPANY/THE MISSION Meissa Vaccines Is Driven to Rid the World of Viral Respiratory Scourges Meissa Vaccines is on a mission to solve a puzzle that has eluded scientists for decades—a pediatric vaccine against respiratory syncytial virus, or RSV. THE PIPELINE Building Single Dose, Intranasal Vaccines to Prevent COVID-19 and RSV Making vaccines […]
The Big4Bio Company to Watch Program
May 2021: Venatorx Pharmaceuticals
May 2021: Venatorx Pharmaceuticals
/ big4bio
THE COMPANY/THE MISSION The Drug Hunter Flying Under the Radar In 2010, Drs. Christopher Burns, Daniel Pevear, and Luigi Xerri set out to build a company focused on anti-infectives; they named it Venatorx, which loosely translated means “Drug Hunter.” THE PIPELINE Addressing the Next Pandemic: Superbugs Venatorx’s lead clinical-stage antibiotics address the growing problem […]
SPOTLIGHT: Big4Bio:SFBay 2020 Year-in-Review
/ big4bio
Welcome to the 2020 Big4Bio Year-in-Review for the San Francisco Bay Area! We hope you enjoy looking back on 2020’s top stories, deals, and M&A that went down in SFBay’s research, pharma, and biotech sectors as we head into 2021. Here’s what you’ll find inside the Year-in-Review 2020 report: Facts about the Bay Area’s life […]
Spotlight Q&A: TFF Pharmaceuticals – Innovative Drug Formulation May Expand Geographic Reach of COVID-19 Vaccines and Treatments
/ big4bio
LaVoieHealthScience Client Spotlight Following is a Q&A with Glenn Mattes, President, CEO and Director of TFF Pharmaceuticals (Nasdaq: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology platform. Welcome to Big4Bio, Mr. Mattes. Can you share with our readers what is important about […]
Spotlight Q&A: Outlook Therapeutics — Developing First Ophthalmic Formulation of Bevacizumab for FDA Approval
/ big4bio
LaVoieHealthScience Client Spotlight Following is a Q&A with Lawrence Kenyon, President, CEO and CFO of Outlook Therapeutics (NASDAQ: OTLK), a late-stage clinical biotech company focused on developing the first FDA-approved ophthalmic formulation of bevacizumab-vikg to treat wet age-related macular degeneration (wet AMD) and other retinal diseases. By way of background for our readers, age-related macular […]
Big4Bio Q&A: Dror Bashan, CEO of Protalix BioTherapeutics
/ big4bio
LaVoieHealthScience Client Spotlight with Dror Bashan, CEO of Protalix BioTherapeutics Can you provide a brief overview of Protalix BioTherapeutics and its focus? Protalix BioTherapeutics is a unique biopharmaceutical company dedicated to bringing to market recombinant therapeutic proteins with clinically improved profiles, produced with our ProCellEx® plant cell-based expression. Protalix was the first company ever to gain FDA approval for […]